Redeye leaves a comment following ExpreS2ion’s announcement of updated Phase I progress and refinements to the ES2B-C001 development strategy. We are encouraged by the continued strong immunogenicity data, with anti-HER2 antibody responses now observed in all evaluable patients and no safety concerns identified, while the expanded Phase I programme and more focused Phase II plan suggest increasing strategic maturity and may strengthen both partnering optionality and ExpreS2ion’s ability to advance the programme independently.
LÄS MER
